Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Academic rigor, journalistic flair
Articles on mRNA
Displaying all articles
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Traditional vaccines can take years to create. Rather than immunizing people with viral proteins, the new approach gives the molecular instructions that allows the body to make its own vaccine.
Top contributors
-
Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
-
Professor of Medicine, University of Virginia
-
Associate Professor of Pediatrics, Vanderbilt University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Associate Professor and ARC Future Fellow, University of Western Australia
-
PhD Candidate, Quantitative Life Sciences, McGill University
